Sodium tanshinone IIA sulfonate attenuates the transforming growth factor-β1-induced differentiation of atrial fibroblasts into myofibroblasts in vitro

Yang,Le; Hu,Jin; Hao,Hong-Zhen; Yin,Zhao; Liu,Gang; Zou,Xiao-Jing

doi:10.3892/ijmm.2015.2087

Sodium tanshinone IIA sulfonate attenuates the transforming growth factor-β1-induced differentiation of atrial fibroblasts into myofibroblasts in vitro

Authors:
- Le Yang
- Jin Hu
- Hong-Zhen Hao
- Zhao Yin
- Gang Liu
- Xiao-Jing Zou
View Affiliations

Affiliations: Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Otolaryngology, Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Anesthesiology and Critical Care Medicine, Laboratory of Anesthesiology and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: February 2, 2015 https://doi.org/10.3892/ijmm.2015.2087
Pages: 1026-1032

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The differentiation of atrial fibroblasts into myofibroblasts is a critical event in atrial fibrosis. One of the most important factors in atrial fibroblast differentiation is transforming growth factor-β1 (TGF-β1). Accumulating evidence indicates that sodium tanshinone IIA sulfonate (STS) possesses antifibrotic properties. In this study, we therefore investigated whether STS attenuates the TGF-β1‑induced differentiation of atrial fibroblasts. TGF-β1 enhanced collagen production, collagen synthesis and the expression of collagen type I and III, as shown by hydroxyproline assay, collagen synthesis assay and western blot analysis, respectively. In addition, as shown by immunohistochemistry and western blot analysis, TGF-β1 enhanced the expression of α-smooth muscle actin (α-SMA), which is the hallmark of myofibroblast differentiation. These responses were attenuated by treatment with STS. In addition, STS suppressed the TGF-β1‑induced expression of phosphorylated (p)Smad/pSmad3 expression and nuclear translocation. Furthermore, STS supressed extracellular signal-regulated kinase (ERK) phosphorylation. In conclusion, the current study demonstrates that STS exerts antifibrotic effects by modulating atrial fibroblast differentiation through ERK phosphorylation and the Smad pathway.

View Figures

View References

1	Nattel S and Opie LH: Controversies in atrial fibrillation. Lancet. 367:262–272. 2006. View Article : Google Scholar : PubMed/NCBI
2	Velagapudi P, Turagam MK, Leal MA and Kocheril AG: Atrial fibrosis: a risk stratifier for atrial fibrillation. Expert Rev Cardiovasc Ther. 11:155–160. 2013. View Article : Google Scholar : PubMed/NCBI
3	Garg A and Akoum N: Atrial fibrillation and heart failure: beyond the heart rate. Curr Opin Cardiol. 28:332–336. 2013. View Article : Google Scholar : PubMed/NCBI
4	Jalife J: Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol. 29:20–27. 2014. View Article : Google Scholar
5	Yue L, Xie J and Nattel S: Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res. 89:744–753. 2011. View Article : Google Scholar :
6	Lee KW, Everett TH, Rahmutula D, et al: Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 114:1703–1712. 2006. View Article : Google Scholar : PubMed/NCBI
7	Petrov VV, van Pelt JF, Vermeesch JR, et al: TGF-beta1-induced cardiac myofibroblasts are nonproliferating functional cells carrying DNA damages. Exp Cell Res. 314:1480–1494. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
9	Schmierer B and Hill CS: TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chen P, Wu R, Zhu W, et al: Hypoxia preconditioned mesenchymal stem cells prevent cardiac fibroblast activation and collagen production via leptin. PLoS One. 9:e1035872014. View Article : Google Scholar : PubMed/NCBI
11	Leask A: Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 106:1675–1680. 2010. View Article : Google Scholar : PubMed/NCBI
12	Peng H, Carretero OA, Peterson EL and Rhaleb NE: Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Am J Physiol Heart Circ Physiol. 298:H1357–H1364. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lee MK, Pardoux C, Hall MC, et al: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26:3957–3967. 2007. View Article : Google Scholar : PubMed/NCBI
14	Gao S, Liu Z, Li H, Little PJ, Liu P and Xu S: Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 220:3–10. 2012. View Article : Google Scholar
15	Yang R, Liu A, Ma X, Li L, Su D and Liu J: Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol. 51:396–401. 2008. View Article : Google Scholar : PubMed/NCBI
16	Jiang FL, Leo S, Wang XG, et al: Effect of tanshinone IIA on cardiomyocyte hypertrophy and apoptosis in spontaneously hypertensive rats. Exp Ther Med. 6:1517–1521. 2013.PubMed/NCBI
17	Xu S and Liu P: Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 23:149–153. 2013. View Article : Google Scholar
18	Yang L, Zou XJ, Gao X, et al: Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med. 41:508–516. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wang P, Zhou S, Xu L, et al: Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: blockade by tanshinone IIA. J Ethnopharmacol. 145:152–161. 2013. View Article : Google Scholar
20	Tsai CT, Lai LP, Kuo KT, et al: Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation. 117:344–355. 2008. View Article : Google Scholar : PubMed/NCBI
21	Peng H, Carretero OA, Raij L, Yang F, Kapke A and Rhaleb NE: Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension. 37:794–800. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zhang H, Pi R, Li R, et al: PPARbeta/delta activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Arch Biochem Biophys. 460:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhang DH, Cohn L, Ray P, Bottomly K and Ray A: Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem. 272:21597–21603. 1997. View Article : Google Scholar : PubMed/NCBI
24	Wang YS, Li SH, Guo J, et al: Role of miR-145 in cardiac myofibroblast differentiation. J Mol Cell Cardiol. 66:94–105. 2014. View Article : Google Scholar
25	Wang H, Leinwand LA and Anseth KS: Roles of transforming growth factor-β1 and OB-cadherin in porcine cardiac valve myofibroblast differentiation. FASEB J. 28:4551–4562. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wu M, Han M, Li J, et al: 17beta-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation. Eur J Pharmacol. 616:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
27	Peng H, Carretero OA, Peterson EL, et al: N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts. Pflugers Arch. 464:415–423. 2012. View Article : Google Scholar : PubMed/NCBI
28	Liu X, Sun SQ, Hassid A and Ostrom RS: cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol. 70:1992–2003. 2006. View Article : Google Scholar : PubMed/NCBI
29	Chen LX, Yang K, Sun M, et al: Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation. Pharmazie. 67:452–456. 2012.PubMed/NCBI
30	Wickramasinghe SR and Patel VV: Local innervation and atrial fibrillation. Circulation. 128:1566–1575. 2013. View Article : Google Scholar : PubMed/NCBI
31	Iwasaki YK, Nishida K, Kato T and Nattel S: Atrial fibrillation pathophysiology: implications for management. Circulation. 124:2264–2274. 2011. View Article : Google Scholar : PubMed/NCBI
32	Magnani JW, Rienstra M, Lin H, et al: Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 124:1982–1993. 2011. View Article : Google Scholar : PubMed/NCBI
33	Uesaka Y: Cerebral embolism and atrial fibrillation. Brain Nerve. 65:761–769. 2013.In Japanese. PubMed/NCBI
34	Burstein B, Libby E, Calderone A and Nattel S: Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation. 117:1630–1641. 2008. View Article : Google Scholar : PubMed/NCBI
35	Brown RD, Ambler SK, Mitchell MD and Long CS: The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 45:657–687. 2005. View Article : Google Scholar : PubMed/NCBI
36	Bosman FT and Stamenkovic I: Functional structure and composition of the extracellular matrix. J Pathol. 200:423–428. 2003. View Article : Google Scholar : PubMed/NCBI
37	Jugdutt BI: Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 3:1–30. 2003. View Article : Google Scholar : PubMed/NCBI
38	Dobaczewski M, Chen W and Frangogiannis NG: Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 51:600–606. 2011. View Article : Google Scholar :
39	Brooks WW and Conrad CH: Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice. J Mol Cell Cardiol. 32:187–195. 2000. View Article : Google Scholar : PubMed/NCBI
40	Youn JY, Zhang J, Zhang Y, et al: Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol. 62:72–79. 2013. View Article : Google Scholar : PubMed/NCBI
41	Weber KT, Sun Y, Bhattacharya SK, Ahokas RA and Gerling IC: Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 10:15–26. 2013. View Article : Google Scholar
42	Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 71:549–574. 2014. View Article : Google Scholar
43	Friedrichs K, Klinke A and Baldus S: Inflammatory pathways underlying atrial fibrillation. Trends Mol Med. 17:556–563. 2011. View Article : Google Scholar : PubMed/NCBI
44	Tang W and Eisenbrand G: Salvia miltiorrhiza Bge. Chinese drugs of plant origin. Springer-Verlag; Berlin: pp. 891–902. 1992, View Article : Google Scholar
45	Yang L, Zou X, Liang Q, et al: Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway. Exp Mol Med. 39:65–73. 2007. View Article : Google Scholar : PubMed/NCBI
46	Shan H, Li X, Pan Z, et al: Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol. 158:1227–1235. 2009. View Article : Google Scholar : PubMed/NCBI
47	Yi SL, Liu XJ, Zhong JQ and Zhang Y: Role of caveolin-1 in atrial fibrillation as an anti-fibrotic signaling molecule in human atrial fibroblasts. PLoS One. 9:e851442014. View Article : Google Scholar : PubMed/NCBI
48	Rahmutula D, Marcus GM, Wilson EE, et al: Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc Res. 99:769–779. 2013. View Article : Google Scholar : PubMed/NCBI
49	Cucoranu I, Clempus R, Dikalova A, et al: NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 97:900–907. 2005. View Article : Google Scholar : PubMed/NCBI
50	Wei LH, Huang XR, Zhang Y, et al: Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc Res. 99:665–673. 2013. View Article : Google Scholar : PubMed/NCBI
51	Yue J and Mulder KM: Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem. 275:30765–30773. 2000. View Article : Google Scholar : PubMed/NCBI
52	Leask A and Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
53	de Caestecker MP, Parks WT, Frank CJ, et al: Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev. 12:1587–1592. 1998. View Article : Google Scholar : PubMed/NCBI
54	Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 63:423–432. 2004. View Article : Google Scholar : PubMed/NCBI